<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02486497</url>
  </required_header>
  <id_info>
    <org_study_id>SNUBH-IMGPB-2015-01</org_study_id>
    <nct_id>NCT02486497</nct_id>
  </id_info>
  <brief_title>Adjuvant Gemcitabine Versus 5-FU/Leucovorin Based on hENT1 Immunostaining</brief_title>
  <official_title>Adjuvant Gemcitabine Versus 5-FU/Leucovorin Based on hENT1 Immunostaining After Curative Surgery of Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IlDong Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human equilibrative nucleoside transporter 1 (hENT1) is a membrane transporter which is a
      predicting marker for gemcitabine chemotherapy. However, there is a limited evidence of it as
      an indicator for adjuvant gemcitabine chemotherapy. In this study, investigators try to
      investigate the role of hENT1 as a indicator of selection of adjuvant chemotherapy regimen
      between gemcitabine and 5-fluorouracil (5-FU).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After surgical resection of pancreatic cancer, the tissue is immunostained by hENT1 antibody.
      The grades of immunostaining are categorized as 0 (0%), 1 (&lt;50%), and 2 (&gt;=50%). According to
      the grade, patients with grade 0 or 1 will be treated with 5-FU and those with grade 2 will
      be treated with gemcitabine. After the study, investigators will calculate the overall
      survival and recurrence free survival of the patients and investigate the role of hENT1 as a
      predictive biomarker for adjuvant gemcitabine chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence free survival</measure>
    <time_frame>Upto 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Upto 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Upto 24 weeks</time_frame>
    <description>Hematologic and hepatic toxicity according to blood test results &amp; non-hematologic toxicity (fatigue, vomiting, diarrhea, sensory neuropathy) according to CTCAE 4.0 scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>5-FU group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Grades of hENT1 immunostaining are 0 or 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Grade of hENT1 immunostaining is 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>hENT1</intervention_name>
    <description>hENT1 is a membrane transporter for gemcitabine. According to the hENT1 staining, patients will be treated with gemcitabine or 5-FU.</description>
    <arm_group_label>5-FU group</arm_group_label>
    <arm_group_label>Gemcitabine group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with curatively resected pancreatic cancer

          -  Age between 18 and 75

          -  Eastern Cooperative Oncology Group performance score 0 or 1

          -  Patients with compliance

          -  Patients with informed consent

        Exclusion Criteria:

          -  Patients refuse to enroll this study

          -  Patients with concomitant chemoradiation therapy

          -  Previous chemotherapy

          -  Pregnant or preparing a pregnancy

          -  Uncontrolled infection, diabetes, hypertension, ischemic heart disease, myocardial
             infarction within 6 months

          -  Enrolled another clinical trial within 30 days

          -  Patients will be expected to be risk because of enrollment

          -  Patients without informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi-do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2015</study_first_submitted>
  <study_first_submitted_qc>June 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2015</study_first_posted>
  <last_update_submitted>September 21, 2017</last_update_submitted>
  <last_update_submitted_qc>September 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic cancer</keyword>
  <keyword>Adjuvant chemotherapy</keyword>
  <keyword>hENT1</keyword>
  <keyword>Gemcitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

